The phase II clinical study EV-201 evaluating the antibody-drug conjugate Padcev (enfortumab vedotinejfv) for treatment of urothelial cancer demonstrated a 52% overall response rate in the second cohort.
To access this subscriber-only content please log in or renew your subscription.
Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.
Login Subscribe
Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.
Login Subscribe